Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal -ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy
- 10 July 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 323, 71-82
- https://doi.org/10.1016/j.jconrel.2020.04.016
Abstract
No abstract availableFunding Information
- Parke-Davis Endowed Chair
- Rutgers University, New Jersey, USA
- Rutgers University
This publication has 63 references indexed in Scilit:
- Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activityExperimental Hematology, 2013
- Ductal Carcinoma In Situ of the BreastInternational Journal of Surgical Oncology, 2012
- Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumorsBreast Cancer Research and Treatment, 2012
- Preclinical and Clinical Evaluation of Intraductally Administered Agents in Early Breast CancerScience Translational Medicine, 2011
- The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathwayOncogene, 2011
- Status of Intraductal Therapy for Ductal Carcinoma in SituCurrent Breast Cancer Reports, 2010
- The antitumor activity of the fungicide ciclopiroxInternational Journal of Cancer, 2010
- Application of Metal Coordination Chemistry To Explore and Manipulate Cell BiologyChemical Reviews, 2009
- Gene expression profiling of the tumor microenvironment during breast cancer progressionBreast Cancer Research, 2009
- Characterization of crystalline L-carnosine Zn(II) complex (Z-103), a novel anti-gastric ulcer agent: Tautomeric change of imidazole moiety upon complexation.CHEMICAL & PHARMACEUTICAL BULLETIN, 1990